Eli Lilly Q3 Revenue Surges 39% on Mounjaro, Zepbound Demand

Eli Lilly reported Q3 revenue of $24.4 billion, up 39% and above the $22.58 billion estimate. Adjusted EPS of $7.48 beat the $5.68 consensus. Mounjaro sales rose 65% to $10.72 billion; Zepbound rose 49% to $5.35 billion. The company raised full-year revenue guidance to $91-$92 billion but trimmed adjusted EPS guidance to $35-$36 due to IPR&D charges. Shares rose 3.3% premarket to $1,331.